Paderno Dugnano

Researchers are conducting an observational, prospective, multicenter study in Italian cardiology centers to evaluate how well patients with Heart Failure with Reduced Ejection Fraction (HFrEF) follow guideline-recommended treatments. The study also aims to assess the safety of these treatments, monitor treatment patterns in patients with acute heart failure, and observe treatment approaches in all chronic heart failure patients regardless of their ejection fraction levels. The study involves two phases of educational interventions and data collection. Initially, healthcare providers will receive education on guideline recommendations and treatment patterns, followed by 3 months of patient data collection or up to 30 consecutive patients with chronic or acute heart failure. After 6 months, treatment modifications and outcomes will be evaluated. Then, a second educational session will highlight gaps between guidelines and practice, followed by another 3 months of data collection. Patients will be followed for 12 months total, with ongoing monitoring of treatment changes and outcomes. Participants will be assessed at enrollment and during the follow-up periods through clinical evaluations and data collection on treatment adherence and safety. The main outcome measured is adherence to guideline-directed medical therapies over 6 months. The study includes evaluations at 6 and 12 months after enrollment, with close monitoring of treatment patterns and patient health status throughout the study duration.

Researchers are creating and managing a national Italian database to study patients with hypoparathyroidism or pseudohypoparathyroidism, two rare diseases affecting parathyroid function and calcium balance. The study aims to collect detailed medical, genetic, clinical, and treatment data from a wide group of patients across Italy to better understand these conditions, their prevalence, and incidence. This research will help improve knowledge about different forms of these diseases and support optimal care planning. The study involves 41 specialist centers throughout Italy, including endocrinology and pediatric departments, where patients with these conditions are treated. Data will be gathered both retrospectively from medical records at the time of recruitment and prospectively during follow-up visits over a 10-year period. No new treatments or interventions are administered by the study; instead, information on patients' usual treatments and responses will be collected. Participants will have their medical histories, clinical features, bone health, laboratory results, and quality of life monitored regularly as part of their usual care. The study will assess disease characteristics, bone fragility, and treatment responses over time, aiming for long-term analysis up to 10 years. Data will be collected anonymously and analyzed to improve understanding and management of these rare diseases.

Researchers are creating and managing a national multicenter database to study patients with parathyroid carcinoma or atypical parathyroid adenoma in Italy. These two rare types of parathyroid gland cancers represent about 1% of all parathyroid tumors. The goal is to collect detailed anamnestic, diagnostic, genetic, clinical, histological, and therapeutic information from a wide group of patients to improve understanding and management of these diseases. The study will take place at 33 specialized endocrinology and endocrine surgery centers across Italy, enrolling patients from all 20 regions. It includes two groups: patients with parathyroid carcinoma and those with atypical parathyroid adenoma, both sporadic and genetic cases. Data collection is both retrospective, using existing medical records at the time of recruitment, and prospective, following patients over a 10-year period during their regular clinical visits. The study does not involve any new treatments or interventions but records responses to standard surgeries and medications used in patient care. Participants will be followed through their usual medical visits at recruiting centers, with data collected anonymously and analyzed collectively. Information gathered includes demographics, family history, lifestyle, clinical history, diagnostic imaging and tests, surgery details, histological findings, genetic testing results, post-operative follow-up, and therapy outcomes. The study aims to evaluate the prevalence and incidence of these tumors, differentiate clinical and biological features, and assess therapy responses over short and long terms to inform tailored treatments. The overall participation can last up to 10 years from enrollment.

Researchers are investigating how diets enriched with polyunsaturated fatty acids (PUFAs) from animal and plant sources affect chronic inflammation linked to cardiovascular disease risk. This study focuses on adults over 55 years old with moderate to high cardiovascular risk but without existing cardiovascular disease. The goal is to understand how lipid-driven inflammation can be managed through simple dietary changes, especially by comparing the impact of fish oil and Camelina Sativa oil supplements to a non-enriched diet. Participants will be randomly assigned to one of three groups: one receiving 4 grams of fish oil daily (containing DHA and EPA), another receiving 10 grams of Camelina Sativa oil daily (rich in ALA) plus vitamin E, and a control group receiving a regular diet with vitamin E. The supplementation period lasts 12 weeks, with oils administered as liquids before meals. Vitamin E is included to balance its levels across groups due to differing contents in the oils. During the study, participants will have clinical visits at the beginning and end of the 12 weeks, including blood sample collection for lipid and inflammation biomarker analysis, as well as measurements of heart rate, blood pressure, and waist circumference. They will also complete dietary questionnaires at these times. Researchers will assess changes in a lipid/inflammation risk score and participants' acceptance of the different PUFA supplements to develop practical tools for controlling cardiovascular inflammation through diet.